Esketamine nasal spray offers rapid benefit in patients at risk of suicide
The Brown University Psychopharmacology Update September 1, 2020 DOI: 10.1002/pu.30614 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Population | Patients with major depressive disorder and active suicidal ideation with intent |
| Intervention | Esketamine nasal spray |
| Duration | 4 weeks |
| Topics | Esketamine |
| Key points | Esketamine nasal spray reduced depressive symptoms rapidly over a 4-week period in patients with major depressive disorder and active suicidal ideation with intent, a condition for which no approved therapeutic currently exists. |
Abstract
Esketamine nasal spray acted rapidly to reduce depressive symptoms in a 4‐week study of patients with major depressive disorder and active suicidal ideation with intent. The results offer promise for emergency treatment of a condition for which there is currently no approved therapeutic. Study results were published online May 12, 2020, in the Journal of Clinical Psychiatry.